Pharmaceuticals company Dr. Reddy's Laboratories announced Q3FY25 results Revenue: Rs 83,586 million, change Up: 16% YoY, 4% QoQ. Gross Margin: 58.7%for Q3FY25, compared to Q3FY24: 58.5% & Q2FY25: 59.6%. EBITDA: Rs 22,982 million 27.5% of Revenues. Profit before Tax: Rs 18,742 million Up: 3% YoY & Down: 2% QoQ. Profit after Tax: Rs 14,133 million Up: 2% YoY & 13% QoQ. G V Prasad, Co-Chairman & MD, Dr. Reddy's Laboratories, said: "We delivered double digit growth aided by our newly acquired NRT business, new launches and improved operational efficiencies. We remain committed to addressing patient needs by advancing healthcare through access, affordability and innovation." Result PDF